BiotechTube

Dexmedetomidine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

ICU Sedation

Conditions

ICU Sedation

Trial Timeline

Mar 21, 2017 → May 21, 2018

NCT ID
NCT03813277

About Dexmedetomidine

Dexmedetomidine is a approved stage product being developed by Orion Corporation for ICU Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT03813277. Target conditions include ICU Sedation.

What happened to similar drugs?

8 of 20 similar drugs in ICU Sedation were approved

Approved (8) Terminated (2) Active (12)
🔄AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
✅Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
✅fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
🔄Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
🔄Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT03813277ApprovedCompleted
NCT02252523Phase 2UNKNOWN
NCT01266252Phase 3Completed
NCT00747721Phase 1Completed
NCT00226785Phase 3Terminated

Competing Products

20 competing products in ICU Sedation

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
40
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
35
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
43
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
38
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
32
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
29
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
39
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
29
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
25
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
35
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
34